CURRICULUM VITAE

FOR

LaShonda C. Knaff, MA

CURRENT POSITION

Title:	Clinical Research Coordinator
Institution:	WR-ClinSearch 6035 Shallowford Rd. Suite 109 Chattanooga, TN 37421
Office Phone:	(423) 698-4584
Fax Number:	(423) 698-4577

PROFESSIONAL EXPERIENCE

06/16-Present	Clinical Research Coordinator, Medical Assistant WR-ClinSearch
05/15-06/16	Clinical Research Assistant, Medical Assistant WR-ClinSearch
10/13-04/15	Certified Nursing Assistant St. Barnabas @ Siskins Hospital
07/11-04/13	Certified Nursing Assistant/Medical Assisting Externship Summit View of Farragut
10/10-06/11	Certified Nursing Assistant Brakebill Nursing Home
09/07-08/10	Certified Nursing Assistant, Restorative CNA Briarcliff Healthcare Center
07/06-02/07	Clinical Research Assistant New Orleans Center for Clinical Research

EDUCATION

2009-2012	National College of Business & Technology Knoxville, TN Medical Assisting Program
2005-2006	Tennessee Technology Ctr of Knoxville Knoxville, TN Phlebotomy Technician Program

2002-2002 American Red Cross
Knoxville, 1N
Certified Nursing Assistant

RESEARCH TRAINING/CERTIFICATIONS

2013 CPR

2015 CITI group certification - GCP

RESEARCH EXPERIENCE

Neurology- Migraine- Protocol: ALD403-CLIN-005-A Parallel Group, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Phase 2 Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALD403 Administered Intravenously in Patients with Chronic Migraine

Gastrology- Opioid-Induced Constipation - Protocol: MCP-103-309-P-01-A Phase 3, Randomized, Double-Blind, Placebo-controlled, Parallel-group Trial of Linaclotide (72 ug or 145 ug) Administered Orally for 12 Weeks to Patients with Chronic Idiopathic Constipation

Health and Wellness - Obesity-Protocol: Camellia-APD356-G000-401- Obesity W/CV risk-A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment with BELVIQ (lorcaserin HCI) on the Incident of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk Factors

Gastrology- Ulcerative Colitis - Protocol: GA-28950-PHASE III, Double Blind, Placebo-Controlled, Multicenter study of the efficacy and safety of Etrolizumab during induction and maintenance in patients with moderate to severe active ulcerative colitis, who are refractory to or intolerant of TNF inhibitors

Gynecology- HSDD-Protocol: PLNBMT-302 HSDD-A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremela otide in Premenopausal Women with Hypoactive Sexual Disorder (HSDD) (with or without Decreased Arousal)

Immunology-Gout-Protocol: Takeda TMX-67_301Gout-A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in subjects with Gout and Cardiovascular Comorbidities

Gastrology- Chronic Idiopathic Constipation - Protocol: SP304203-0I CIC Rollover-An Open-Label Extension, Long Term Safety and Tolerability study of Placanatide in Patients with Chronic Idiopathic Constipation

Gastrology- Diabetic Gastroparesis - Protocol: ICP-112-202-A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once and Twice Daily for 4 Weeks to Patients with Diabetic Gastroparesis

Dermatology-Atopic Dermatitis-Protocol: SYM2014-03- A Double-Blind, Randomized, Parallel- Group, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of a Generic Pimecrolimus Cream, 1% and Reference Listed Elide! (Pimecrolimus Cream, 1%) and Compare Both Active Treatments to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis

Dermatology-Atopic Dermatitis-Protocol: R668-AD-1334-A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients with Moderate-To-Severe Atopic Dermatitis

Gastrology- Irritable Bowel Syndrome -Constipation - Protocol: ICP-103-307-A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 weeks to Patients with Irritable Bowel Syndrome with Constipation (IBS-C)

Hepatic- NASH-Protocol: NASH-652-2-203 Liver Fibrosis- CENTAUR - Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects with Liver Fibrosis

Cardiology- STRENGTH- Protocol: D5881c00004-A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia

Health and Wellness -Type 2 Diabetes Mellitus - Protocol: MK-8835-017-A Phase 3, Randomized, double blind, placebo-controlled, parallel-group, multicenter clinical trial to evaluate the efficacy and safety of the initial combination of Ertugliflozin (MK-8835/PF- 04971729) with Sitagliptin in the treatment of subjects with T2DM with inadequate glycemic control on diet and excerise.

Gastrology- Crohns - Protocol: RHB-104-01-A Phase III Randomized, Double Blind, Placebo- controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects with Moderately to Severely Active Crohn's Disease

Gastrology- Constipation- Protocol: BLI400-3_01-A Safety and Efficacy Evaluation of BLI400 Laxative in constipated adults.

Neurology- Migraine - Protocol: 20120297 -A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention

Gastrology - Constipation - Protocol: BLIS0l-204 - A Pilot Study of BLI801 Laxative in Adults Experiencing Non-Idiopathic Constipation

Neurology - Fibromyalgia - Protocol: DS5565-A-E310 - A Randomized, Double-Blind, Placebo and Active Controlled Study of DS5565 in Subjects with Pain Associated with Fibromyalgia

Neurology - Migraine - Protocol - J5Q-MC-CGAI - A Phase 3, Randomized, Double-Blind, Placebo- Controlled, Study of LY2951742 in Patients with Chronic Migraine

Neurology - Migraine - Protocol - ISQ-MC-CGAG - A Phase 3, Randomized, Double-Blind, Placebo- Controlled, Study of L Y2951742 in Patients with Episodic Migraine

Neurology - Fibromyalgia - Protocol: 8062-CL-0101 - A Randomized, Double-Blind Placebo controlled, Parallel-group Study to Assess the Analgesic Efficacy and Safety of ASP8062 in subjects with Fibromyalgia.

Dermatology-Atopic Dermatitis-Protocol: PMLC 1603-A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence of a Generic Pimecrolimus Cream, 1% (Taro Pharmaceuticals USA, Inc.) to the Marketed Product ELIDEL® (pimecrolimus) Cream, 1% (Valeant Pharmaceuticals North America LLC) in the Treatment of Mild to Moderate Atopic Dermatitis.

Gastrology-Blood draw study- Protocol: BB-GI-060-A Clinical Sample Collection from multiple Gastrointestinal Indications and Liver Panel Markers.

Gastrology – Observational Study- Protocol: EAV-20216-01- A Psychometric Evaluation of the ANMS Gastroparesis Cardinal Symptom Index

LaShonda Knaff
Signature

1-24-2018
Date

COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM)

COMPLETION REPORT - PART 1 OF 2
COURSEWORK REQUIREMENTS*

* NOTE: Scores on this Requirements Report reflect quiz completions at the time all requirements for the course were met. See list below for details. See separate Transcript Report for more recent quiz scores, including those on optional (supplemental) course elements.

- **Name:** LaShonda Knaff (ID: 4809727)
- **Institution Affiliation:** SCRS (ID: 1324)
- **Institution Email:** lknaff@clinsearch-us.com
- **Institution Unit:** Research
- **Phone:** 423-698-4584

- **Curriculum Group:** CITI Good Clinical Practice
- **Course Learner Group:** Good Clinical Practice Course (ICH Focus) for Coordinators
- **Stage:** Stage 2 - GCP Refresher
- **Description:** **This ICH E6 GCP Investigator Site Training meets the Minimum Criteria for ICH GCP Investigator Site Personnel Training identified by TransCelerate BioPharma as necessary to enable mutual recognition of GCP training among trial sponsors.**

- **Record ID:** 22149444
- **Completion Date:** 30-Jan-2017
- **Expiration Date:** 30-Jan-2020
- **Minimum Passing:** 80
- **Reported Score*:** 91

REQUIRED AND ELECTIVE MODULES ONLY	DATE COMPLETED	SCORE
GCP Refresher - International Conference on Harmonisation (ICH): GCP Requirements (ID: 16779)	30-Jan-2017	3/5 (60%)
GCP Refresher - Investigator's Responsibilities and GCP (ID: 16780)	30-Jan-2017	4/5 (80%)
GCP Refresher - Informed Consent (ID: 16781)	30-Jan-2017	5/5 (100%)
GCP Refresher - Safety Management (ID: 16782)	30-Jan-2017	5/5 (100%)
GCP Refresher - Investigational Product (Drug) Management (ID: 16783)	30-Jan-2017	5/5 (100%)
GCP Refresher - Audits, Inspection, and Monitoring of Research Studies (ID: 16784)	30-Jan-2017	5/5 (100%)
GCP Refresher - Sponsor Responsibilities and GCP (ID: 16785)	30-Jan-2017	5/5 (100%)

For this Report to be valid, the learner identified above must have had a valid affiliation with the CITI Program subscribing institution identified above or have been a paid Independent Learner.

Verify at: www.citiprogram.org/verify/?kcde1ff57-9b19-4ed7-81e6-199b9efdd6fa-22149444

Collaborative Institutional Training Initiative (CITI Program)
Email: support@citiprogram.org
Phone: 888-529-5929
Web: https://www.citiprogram.org

COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM)

COMPLETION REPORT - PART 2 OF 2
COURSEWORK TRANSCRIPT**

** NOTE: Scores on this Transcript Report reflect the most current quiz completions, including quizzes on optional (supplemental) elements of the course. See list below for details. See separate Requirements Report for the reported scores at the time all requirements for the course were met.

- **Name:** LaShonda Knaff (ID: 4809727)
- **Institution Affiliation:** SCRS (ID: 1324)
- **Institution Email:** lknaff@clinsearch-us.com
- **Institution Unit:** Research
- **Phone:** 423-698-4584

- **Curriculum Group:** CITI Good Clinical Practice
- **Course Learner Group:** Good Clinical Practice Course (ICH Focus) for Coordinators
- **Stage:** Stage 2 - GCP Refresher
- **Description:** **This ICH E6 GCP Investigator Site Training meets the Minimum Criteria for ICH GCP Investigator Site Personnel Training identified by TransCelerate BioPharma as necessary to enable mutual recognition of GCP training among trial sponsors.**

- **Record ID:** 22149444
- **Report Date:** 30-Jan-2017
- **Current Score**:** 91

REQUIRED, ELECTIVE AND SUPPLEMENTAL MODULES	MOST RECENT	SCORE
GCP Refresher - International Conference on Harmonisation (ICH): GCP Requirements (ID: 16779)	30-Jan-2017	3/5 (60%)
GCP Refresher - Investigator's Responsibilities and GCP (ID: 16780)	30-Jan-2017	4/5 (80%)
GCP Refresher - Informed Consent (ID: 16781)	30-Jan-2017	5/5 (100%)
GCP Refresher - Safety Management (ID: 16782)	30-Jan-2017	5/5 (100%)
GCP Refresher - Investigational Product (Drug) Management (ID: 16783)	30-Jan-2017	5/5 (100%)
GCP Refresher - Audits, Inspection, and Monitoring of Research Studies (ID: 16784)	30-Jan-2017	5/5 (100%)
GCP Refresher - Sponsor Responsibilities and GCP (ID: 16785)	30-Jan-2017	5/5 (100%)
SCRS (ID: 12776)	16-Jun-2015	No Quiz

For this Report to be valid, the learner identified above must have had a valid affiliation with the CITI Program subscribing institution identified above or have been a paid Independent Learner.

Verify at: www.citiprogram.org/verify/?kcde1ff57-9b19-4ed7-81e6-199b9efdd6fa-22149444

Collaborative Institutional Training Initiative (CITI Program)
Email: support@citiprogram.org
Phone: 888-529-5929
Web: https://www.citiprogram.org